Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Search
  • Twitter

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Publications
  • Posters
  • Media Resources

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application

December 23, 2013

Titan Pharmaceuticals Announces Third Quarter 2013 Financial Results

November 14, 2013

Titan Pharmaceuticals Announces $5 Million Equity Investment and Restructuring of Probuphine Partnership

November 13, 2013

Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2013 Financial Results

November 8, 2013

Titan Pharmaceuticals Announces Confirmation of Meeting With FDA Regarding Probuphine

September 26, 2013

Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine

September 4, 2013

Titan Pharmaceuticals Announces Second Quarter 2013 Financial Results

August 14, 2013

Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction

August 13, 2013

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2013 Financial Results

August 8, 2013

Titan Pharmaceuticals Announces Amendment to Partnership With Braeburn Pharmaceuticals

May 29, 2013

  • 1
  • 2
  • Next »
© 2023 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap Twitter